Rollins Financial’s iShares Biotechnology ETF IBB Stock Holding History

Rollins Financial’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,728	Closed	-$358K	–	125
2022 Q4	$358K	Buy	2,728 +5	+0.2%	+$646	0.14%	81
2022 Q3	$318K	Sell	2,723 -965	-26%	-$120K	0.12%	76
2022 Q2	$434K	Sell	3,688 -2,633	-42%	-$313K	0.15%	66
2022 Q1	$824K	Sell	6,321 -1,093	-15%	-$142K	0.24%	45
2021 Q4	$1.13M	Buy	+7,414	New	+$1.15M	0.33%	31
2021 Q2	$2M	Buy	12,208 +783	+7%	+$121K	0.73%	25
2021 Q1	$1.72M	Buy	11,425 +278	+2%	+$44.2K	0.74%	23
2020 Q4	$1.69M	Buy	+11,147	New	+$1.59M	0.77%	20

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Rollins Financial's IBB Position: Q1 2023 in Review

Rollins Financial sold out of iShares Biotechnology ETF (IBB) in Q1 2023, closing a stake of 2,728 shares — an estimated $358K sold.

Rollins Financial first reported a position in IBB in Q4 2020 and held it in 8 quarters. The position peaked at $2M in Q2 2021. 866 funds tracked by Wall St. Rank hold IBB as of Q1 2023.

Rollins Financial reported no remaining iShares Biotechnology ETF position as of Q1 2023 after selling out during the quarter.
Rollins Financial sold 2,728 iShares Biotechnology ETF shares in Q1 2023, an estimated $358K.
Rollins Financial first reported a position in iShares Biotechnology ETF in Q4 2020 and held it in 8 quarters.
Rollins Financial's iShares Biotechnology ETF position peaked at $2M in Q2 2021.
866 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2023.

Based on Rollins Financial's 13F filing for Q1 2023, filed 3 May 2023.